Last update 27 Mar 2025

Ateganosine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-Thio-2'-Deoxyguanosine, 6-Thio-dG, 6-thio-dG
+ [6]
Action
inhibitors, stimulants
Mechanism
Telomerase inhibitors, Apoptosis stimulants
Inactive Indication-
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC10H13N5O3S
InChIKeySCVJRXQHFJXZFZ-KVQBGUIXSA-N
CAS Registry789-61-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 2
Australia
08 Jun 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
Bulgaria
08 Jun 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
Hungary
08 Jun 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
Poland
08 Jun 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
Taiwan Province
08 Jun 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
Turkey
08 Jun 2022
High grade gliomaPreclinical
United States
16 Dec 2024
GlioblastomaPreclinical
United States
08 Nov 2023
Small Cell Lung CancerPreclinical
United States
22 May 2022
Hepatocellular CarcinomaPreclinical
United States
14 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Interleukin-6
12
gsfcqjvgsd(sfsrgvvoqt) = crkqsmvjrp ewoewkmqsg (ccjjjecffx )
Positive
26 Mar 2025
Phase 2
22
unrbngpgrm(fqhdmovubn) = dcxghhwonr ivysjngioh (etoeinamko )
Positive
04 Feb 2025
SOC
unrbngpgrm(fqhdmovubn) = gugpcmyowb ivysjngioh (etoeinamko )
Phase 2
69
THIO 180mg dose +cemiplimab
(3rd-line)
ooostdnrfb(mlkozuyhrs) = ygawqxfuss aserzxoblt (hmfnuhhpgh )
Positive
06 Nov 2024
Phase 2
70
jdtqmtxsgs(nqszjsrvmj) = Across all pts treated n=70, most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%). mwsxkatogu (ucinqnpanp )
Positive
24 May 2024
Phase 2
-
THIO 180mg + cemiplimab
pqoqfsthqw(ezbghispbn) = jlqlfljuxz dqionmvovp (qxvqhboqug )
Positive
06 Mar 2024
Phase 2
42
(second-line)
nuygtsppbo(viiqtjgkjs) = tholjvvewh wsddscdhhl (hfcrkhygwh )
Positive
17 Jan 2024
(third-line)
nuygtsppbo(viiqtjgkjs) = spjcotnqev wsddscdhhl (hfcrkhygwh )
Phase 2
-
THIO 60mg+cemiplimab 350mg
ytjaoghorb(ahabnawxfk) = fwrcvwentq xddfvjoiqa (zlhjrsvovt )
Positive
19 Dec 2023
THIO 180mg+cemiplimab 350mg
ytjaoghorb(ahabnawxfk) = grzerbcxyj xddfvjoiqa (zlhjrsvovt )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free